1592 related articles for article (PubMed ID: 16336294)
21. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
22. Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
Erden I; Yalcin S; Ozhan H
Kardiol Pol; 2010 Sep; 68(9):1043-5; discussion 1046. PubMed ID: 20859899
[TBL] [Abstract][Full Text] [Related]
23. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: an observational study of treatment rates and clinical outcome.
Gotsman I; Rubonivich S; Azaz-Livshits T
Isr Med Assoc J; 2008 Mar; 10(3):214-8. PubMed ID: 18494235
[TBL] [Abstract][Full Text] [Related]
24. Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone.
Fujii H; Nakahama H; Yoshihara F; Nakamura S; Inenaga T; Kawano Y
Kobe J Med Sci; 2005; 51(1-2):1-6. PubMed ID: 16199929
[TBL] [Abstract][Full Text] [Related]
25. Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
Muzzarelli S; Maeder MT; Toggweiler S; Rickli H; Nietlispach F; Julius B; Burkard T; Pfisterer ME; Brunner-La Rocca HP;
Am J Cardiol; 2012 Mar; 109(5):693-8. PubMed ID: 22152974
[TBL] [Abstract][Full Text] [Related]
26. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
Matsuda H; Hayashi K; Saruta T
J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
[TBL] [Abstract][Full Text] [Related]
27. Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort.
Abbas S; Ihle P; Harder S; Schubert I
Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):406-13. PubMed ID: 25683504
[TBL] [Abstract][Full Text] [Related]
28. Safety of concomitant potassium-sparing diuretics in angiotensin-converting enzyme inhibitor therapy in severe congestive heart failure. Xamoterol in Severe Heart Failure Study Group.
Bergler-Klein J; Sochor H; Pouleur H; Pacher R; Porenta G; Glogar D
J Cardiovasc Pharmacol; 1994 Aug; 24(2):194-8. PubMed ID: 7526050
[TBL] [Abstract][Full Text] [Related]
29. Clinical experience with spironolactone in pediatrics.
Buck ML
Ann Pharmacother; 2005 May; 39(5):823-8. PubMed ID: 15811903
[TBL] [Abstract][Full Text] [Related]
30. Valsartan in chronic heart failure.
Ripley TL
Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
[TBL] [Abstract][Full Text] [Related]
31. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.
Renke M; Tylicki L; Rutkowski P; Rutkowski B
Scand J Urol Nephrol; 2004; 38(5):427-33. PubMed ID: 15764256
[TBL] [Abstract][Full Text] [Related]
32. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
Fuster D; Frey FJ; Ferrari P
Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
[TBL] [Abstract][Full Text] [Related]
33. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
Bauersachs J; Fraccarollo D
Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
[TBL] [Abstract][Full Text] [Related]
34. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
[TBL] [Abstract][Full Text] [Related]
35. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia?
Raebel MA; McClure DL; Chan KA; Simon SR; Feldstein AC; Lafata JE; Andrade SE; Gunter MJ; Nelson WW; Roblin D; Platt R
Ann Pharmacother; 2007 Feb; 41(2):193-200. PubMed ID: 17284506
[TBL] [Abstract][Full Text] [Related]
36. [A patient with severe hyperkalaemia -- an emergency after RALES].
Nürnberger J; Daul A; Philipp T
Dtsch Med Wochenschr; 2005 Sep; 130(36):2008-11. PubMed ID: 16143930
[TBL] [Abstract][Full Text] [Related]
37. Influence of the angiotensin II receptor antagonist losartan on diuretic-induced metabolic effects in elderly hypertensive patients: comparison with a calcium channel blocker.
Ohnishi K; Kohno M; Yukiiri K; Masugata H; Wada Y; Takagi Y; Ohmori K
Int J Clin Pharmacol Ther; 2001 Oct; 39(10):417-22. PubMed ID: 11680666
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early posttransplant period.
Formica RN; Friedman AL; Lorber MI; Bia MJ
Transplant Proc; 2004 Nov; 36(9):2675-8. PubMed ID: 15621121
[TBL] [Abstract][Full Text] [Related]
39. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials.
de Denus S; Tardif JC; White M; Bourassa MG; Racine N; Levesque S; Ducharme A
Am Heart J; 2006 Oct; 152(4):705-12. PubMed ID: 16996842
[TBL] [Abstract][Full Text] [Related]
40. Renin-angiotensin system blockade is not associated with hyperkalemia in chronic hemodialysis patients.
Lin HH; Yang YF; Chang JK; Ting IW; Kuo HL; Wang IK; Huang CC
Ren Fail; 2009; 31(10):942-5. PubMed ID: 20030530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
